biontech quartalszahlen 2020

BNT411 – On July 8, the first patient was dosed in a Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC). Interim Condensed Consolidated Statements of Cash Flows, 190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png. 11.08.2020 - 14:36 | Quelle: finanztreff | Lesedauer etwa 3 min. We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases von Finanztreff.de, 11.08.2020, 14:36 Uhr Aktien BioNTech Finanzen. The slide presentation and audio of the webcast will be available via the following link: https://edge.media-server.com/mmc/p/jqhpczzu. BioNTech: Die Quartalszahlen sind da! Biontech peilt weiter Impfstoffzulassung im Oktober an - Quartalszahlen Nachrichtenagentur: dpa-AFX | 11.08.2020, 14:16 | 1110 | 0 | 0 General and Administrative Expenses: General and administrative expenses were €18.8 million for the three months ended June 30, 2020, compared to €14.6 million for the three months ended June 30, 2019. Announced initial commercial supply agreements totaling more than 250 million doses with the United Kingdom, the United States, Japan and Canada in 2020 and 2021, with an option to purchase up to an additional 500 million doses. Phase 1/2 placebo-controlled, observer-blinded clinical trial, evaluating nucleoside-modified messenger RNA vaccine candidate (BNT162b1) in 45 subjects, and data from the ongoing Germany trial in 60 subjects. Initiated a Phase 2b/3 study for BNT162b2 in up to 30,000 participants aged 18 to 85 years at approximately 120 sites globally; if successful, BioNTech and Pfizer plan to file for market authorization or regulatory approval as early as October 2020. BioNTech ist heute ganz schön ordentlich gefallen. 10.11.2020 - 05:50 ... zu seinem Corona-Impfstoff legt das Mainzer Pharmaunternehmen Biontech … Pfizer präsentiert in der voraussichtlich am 02.02.2021 stattfindenden Finanzkonferenz das Zahlenwerk zum jüngsten Quartal, welches am 31.12.2020 endete. To participate in the conference call, please dial the following numbers 15-20 minutes prior to the start of the call and provide the Conference ID: 1963889. On July 27, 2020, BioNTech announced the closing of an underwritten offering of 5,500,000 American Depositary Shares (“ADSs”), each representing one of BioNTech’s ordinary shares, at a public offering price of $93.00 per ADS, for gross proceeds of €456.8 million ($511.5 million. BNT131 – BioNTech expects to provide a data update from the Phase 1 trial in solid tumors in 2H 2020. https://edge.media-server.com/mmc/p/jqhpczzu. In Q2 2020 BioNTech received an aggregate of €216.7 million ($236.0 million) in non-refundable upfront payments from the BNT162 collaboration agreements and … Studie in "Rekordzeit" Biontech peilt weiter Impfstoffzulassung im Oktober an - Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. Research and Development Expenses: Research and development expenses were €95.2 million for the three months ended June 30, 2020, compared to €53.4 million for the three months ended June 30, 2019. MAINZ, Germany, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended June 30, 2020. “We made significant progress in the second quarter toward our goal of advancing our oncology programs and toward bringing a COVID-19 vaccine to market as quickly as possible.  I am incredibly proud of our team, who has worked tirelessly to initiate our BNT162 Phase 2b/3 trial in record time and put us in a position to seek regulatory review as early as October of this year, if our trials are successful,” said Ugur Sahin, BioNTech’s CEO and Co-founder. November 2020 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“), ein Unternehmen, das bahnbrechende Immuntherapien der nächsten Generation zur Behandlung von Krebs und Infektionskrankheiten entwickelt, hat heute Informationen zur Geschäftsentwicklung sowie die Quartalszahlen des am 30. Mit vielversprechenden Nachrichten zu seinem Impfstoff hat Biontech große Hoffnungen im Kampf gegen die Corona-Pandemie geschürt. BNT311 – BioNTech expects to provide a data update in 2H 2020, which will include dose-escalation data from the Phase 1/2 trial in multiple solid tumors for GEN1042/BNT311 (PD-L1x4-1BB). Adjustments to reconcile loss before tax to net cash flows: Depreciation and amortization of property, plant, equipment and intangible assets, Loss on disposal of property, plant and equipment, Decrease/(Increase) in trade receivable and contract assets, (Decrease)/Increase in trade payables, other liabilities, contract liabilities and provisions, Purchase of property, plant and equipment, Proceeds from sale of property, plant and equipment, Acquisition of subsidiaries and businesses, net of cash acquired, Proceeds from issuance of share capital, net of costs, Net increase/(decrease) in cash and cash equivalents, Change in cash resulting from exchange rate differences. Finanzergebnisse des dritten Quartals 2020. In addition, from the date of acquisition, the new U.S.-based subsidiary, BioNTech US Inc., contributed to our research and development expenses. SAR441000/BNT131 is partnered with Sanofi. ADRs) Quartalszahlen: 09.08.21: BioNTech SE (spons. All agreements are subject to clinical success and regulatory approval. While the preclinical focus has mainly been on ovarian cancer, patients with uterine, testicular, lung and gastric cancers may also be enrolled. Mainz, Germany, November 3, 2020 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2020 on Tuesday, November 10th, 2020. ET (2:00 p.m. CET) to report its financial results for the quarter ended June 30, 2020 and provide a corporate update. Hier finden Sie Informationen zu dem Thema „Pharma“. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: our expected cash usage for 2020 and beyond; our anticipated cash runway; the timing, completion and extent of subscription of the rights offering; the planned next steps in BioNTech’s pipeline programs and specifically including, but not limited to, statements regarding plans to initiate clinical trials of BioNTech’s product candidates; expectations for data announcements with respect to BioNTech’s clinical trials; the timing for any potential emergency use authorizations or approvals for BNT162; and our ability to scale-up manufacturing capacity for BNT162 and supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. ... Darüber hinaus verkündet das Unternehmen morgen seine Quartalszahlen für Q3 2020. 2 IVAC_M_uID is also being investigated in arm 2 (N=15) of the 3 arm TNBC-MERIT trial, with BNT114 as an optional treatment; BNT114 is investigated in arm 1 (N=12) and arm 3 (N=15) of the TNBC-MERIT trial (total patients in study: N=42). The first adjuvant Phase 2 study is currently recruiting for patients and first patient dosing is expected in 2H 2020. Investor RelationsSylke Maas, Ph.D. VP Investor Relations & Business Strategy Tel: +49 (0)6131 9084 1074 E-mail: Investors@biontech.deÂ, Media RelationsJasmina AlatovicSenior Manager Global External Communications Tel: +49 (0)6131 9084 1513 or +49 (0)151 1978 1385 E-mail: Media@biontech.de, Interim Condensed Consolidated Statements of Financial Position, Interim Condensed Consolidated Statements of Operations. ... September 2020 ergab sich … Cash Position: Cash and cash equivalents as of June 30, 2020, were €573.0 million. United States international:                +1 646 741 3167United States domestic (toll-free):      +1 877 870 9135Germany:                                         +49 692 2222 625. BioNTech Aktie Klingelt morgen mit den Quartalszahlen der Wecker? A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. On June 29, 2020, BioNTech announced the signing of a private investment of €223.9 million ($250.7 million, On June 11, 2020, the European Investment Bank (EIB) and BioNTech entered into a €100.0 million ($112.0 million. For the period of six months ended June 30, 2020, total net loss was €141.7 million, compared to €90.8 million for the comparative prior year period. Am 27. In Q2 2020 BioNTech received an aggregate of €216.7 million ($236.0 million) in non-refundable upfront payments from the BNT162 collaboration agreements and equity investments with Pfizer and Fosun Pharma. BNT221 (NEO-PTC-01) – Initiation of a Phase 1 dose escalation trial of BNT221 is expected in 2H 2020 for the treatment of metastatic melanoma in patients who are refractory or unresponsive to checkpoint inhibitors. The program is partnered with Genmab. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. In addition, from the date of acquisition, our new U.S.-based subsidiary, BioNTech US Inc., contributed to our general and administrative expenses. Certain holders irrevocably agreed not to transfer or exercise their rights in the rights offering, and the shares underlying those rights were offered in the underwritten offering. Net Loss: Net loss was €88.3 million for the three months ended June 30, 2020, compared to €50.1 million for the three months ended June 30, 2019. BioNTech: Die Quartalszahlen sind da! For the period of six months ended June 30, 2020, total research and development expenses were €160.3 million, compared to €110.6 million for the comparative prior year period. To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID: Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.de/. The increase was mainly influenced by higher expenses for purchased management consulting and legal services as well as an increase in headcount leading to higher wages, benefits and social security expenses. * Foreign exchange differences on a cumulative basis are either shown as finance income or expenses and might switch between those two positions during the year-to-date reporting periods. Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was €41.8 million for the three months ended June 30, 2020, compared to €25.8 million for the three months ended June 30, 2019. Released data from the ongoing U.S. 11.08.2020 08:11 Uhr - Autor: Michael Barck auf Twitter Heute wird BioNTech Quartalszahlen vorlegen. Es bleibt spannend um BioNTech. For the period of six months ended June 30, 2020, total general and administrative expenses were €34.6 million, compared to €23.9 million for the comparative prior year period. Die Corona-Infektionszahlen sind … Für die neun Monate bis zum 30. RO7198457 (BNT122/RG6180) is partnered with Genentech. Diese hätten nicht viel Neues parat gehabt, schrieb Analyst Cory Kasimov…. 08.05.2020 BNT111 – BioNTech expects to initiate this Phase 2 trial with registrational potential in the second half of 2020. Dienstag 10.11.2020 21:52 - Finanztreff.de. On July 22, 2020, BioNTech announced the terms of a rights offering of rights to subscribe for ordinary shares, including ordinary shares represented by ADSs, extended to holders of its ordinary shares and ADSs. For more information, please visit www.BioNTech.de Â. | Text vorlesen Stop Pause Fortsetzen facebook twitter BNT122 – Two Phase 2 clinical trials are planned in the adjuvant setting. Investor RelationsSylke Maas, Ph.D.+49 (0)6131 9084 1074Investors@biontech.de, Media RelationsJasmina Alatovic+49 (0)6131 9084 1513 or +49 (0)151 1978 1385Media@biontech.de. BNT111 – On July 30, BioNTech announced the publication of interim Phase 1 data for BNT111, the Company’s lead mRNA-based FixVac cancer vaccine program, in, BNT111 – On July 31, BioNTech and Regeneron Pharmaceuticals, Inc. announced a strategic collaboration to jointly conduct a randomized Phase 2 study for the treatment of melanoma that has progressed after prior PD-1 blockade, utilizing BNT111 FixVac and Regeneron’s Libtayo.

Biontech Quartalszahlen 2020, Tote In Dieburg, Champions League Highlights Dazn, Cheap Guest House In Addis Ababa, Vienna Blood Staffel 2, Wirtschaftsministerium Hessen Organigramm, Why Is Wangari Maathai Important, Oyster Bay Dar Es Salaam Hotel, Kenia Safari Preise, Juventus Vs Porto Dazn, Rx 6900 Xt Mining, Tyler James Williams,